Adverse drug reaction profile of nanoparticle versus conventional formulation of paclitaxel: An observational study
| Autor: | Anup Majumdar, Ballari Brahmachari, Avijit Hazra |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Pharmacology
myalgia medicine.medical_specialty business.industry Nausea Anemia nanoparticle Adverse drug reaction Common Terminology Criteria for Adverse Events medicine.disease Surgery paclitaxel chemistry.chemical_compound Tolerability Paclitaxel chemistry Internal medicine Vomiting Medicine observational study Pharmacology (medical) medicine.symptom business Research Article |
| Zdroj: | Indian Journal of Pharmacology |
| ISSN: | 0253-7613 |
| DOI: | 10.4103/0253-7613.77341 |
| Popis: | Objectives: Conventional polyethoxylated castor oil (PCO)-based paclitaxel is associated with major adverse drug reactions (ADRs). Nanoxel, a nanoparticle-based formulation, may improve its tolerability by removing the need for PCO vehicle, and also permit its use in a higher dose. We conducted intensive monitoring of the ADR profile of Nanoxel in comparison with conventional paclitaxel in a public tertiary care set-up. Materials and Methods: ADR data were collected from 10 patients receiving Nanoxel and 10 age-matched controls receiving conventional paclitaxel in this longitudinal observational study, conducted in a medical oncology ward over 18 months. Severity was graded as per US National Cancer Institute Common Terminology Criteria for Adverse Events. Results: The groups had comparable demography at baseline. The median disease duration and per cycle median dose of paclitaxel were greater in the Nanoxel arm. Total 119 ADRs were noted with Nanoxel and 123 with conventional paclitaxel. Of these, 25 (21.0%, 95% CI 13.69–28.33%) in the Nanoxel and 20 (16.2%, 95% CI 9.74–22.78%) in paclitaxel group were of grade 3/4 severity. Common events included myalgia, nausea, anemia, paresthesia, alopecia, diarrhea, and vomiting with Nanoxel, and paresthesia, anemia, myalgia, anorexia, alopecia, vomiting, diarrhea, stomatitis, and nausea with paclitaxel. Of the less common events ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|